Summary
Intraperitoneal injection of (+)-3-[3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3PPP), a sigma receptor agonist, significantly reduced the striatal levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) measured by in vivo microdialysis. These reductions were significantly greater at (+)-3PPP doses of 12 and 24 mg/kg than at 1 mg/ kg. The levels of 5-hydroxyindoleacetic acid (5HIAA) were increased by the injection of (+)-3PPP in dose of 24 mg/kg, but were not affected at lower doses. BMY-14802, a sigma antagonist, alone at doses of 15 mg/kg and 30 mg/kg did not affect the levels of DA, DOPAC, HVA and 5HIAA. Pretreatment with 30 mg/kg BMY-14802 reversed the reduction of the levels of DA induced by 12 mg/kg (+)-3PPP. Although neither 30 mg/kg BMY-14802 nor 12 mg/kg (+)-3PPP affected the levels of striatal 5HIAA, combined treatment with both produced a significant elevation. These findings clearly demonstrate that sigma receptors may regulate DA release from the striatal presynapse.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amt J, Bogeso KP, Christensen AV, Hyttel J, Larsen J-J, Svendsen O (1983) Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacology 81: 199–207
Ceci A, Smith M, French ED (1988) Activation of A10 mesolimbic system by the σ-receptor agonist (+) SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic drug. Eur J Pharmacol 154: 53–57
De Costa BR, Bowen WD, Hellewell SB, Walker JM, Thurkauf A, Jacobson AE, Rice KC (1989) Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for a receptors. FEBS Lett 251: 53–58
Ferris RM, Harfenist M, McKenzie GM (1982) BW234U, (cis-9-[3-(3,5-dimethyl-l-piperazinyl)propyl]-carbazoledihydrochloride): a novel antipsychotic agent. J Pharm Pharmacol 34: 388–390
Graybiel AM, Besson M-J, Weber E (1989) Neuroleptic sensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia nigra, pars compacta of the cat. J Neurosci 9: 326–338
Gundlach AL, Largent BL, Snyder SH (1986) Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)-3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci 6: 1757–1770
Hjorth S, Carlsson A, Clark D, Svensson K, Wikstrom H, Sanchez D, Lindberg P, Hachsell U, Arvidsson L-E, Johansson A, Nilsson JLG (1983) Central dopamine receptor agonist and antagonist actions of enantiomers of 3-PPP. Psychopharmacology 81: 89–99
Imperato A, Tanda G, Frau R, Di Chiara G (1988) Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J Pharmacol Exp Ther 245: 257–264
Kanzaki A, Akiyama K, Otsuki S (1992) Subchronic methamphetamine treatment enhances ouabain-induced striatal dopamine efflux in vivo. Brain Res 569: 181–188
Koch SW, Koe BK, Bacopoulos NG (1983) Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites. Eur J Pharmacol 92: 279–283
Largent BL, Gundlach AL, Snyder SH (1984) Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]-3-[3-hydroxyphenyl]-N-(l-propyl)piperidine. Proc Natl Acad Sci USA 81: 4983–4987
Largent BL, Wikstrom H, Snowman AM, Snyder SH (1988) Novel antipsychotic drugs share high affinity for σ receptors. Eur J Pharmacol 155: 345–347
Martin WR, Eades CG, Thompson JA, Huppier RE, Gilbert PE (1976) The effects of morphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517–532
Mikuni M, Gudelsky GA, Simonivic M, Meltzer HY (1984) Interaction of (+)- and (−)-3-PPP with the dopamine receptor in the anterior pituitary gland. Life Sci 34: 239–246
Mulder AH, Draper R, Smimia P, Schoffelmeer ANM, Stoof JC (1985) Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and presynaptic dopamine receptors in vitro. Eur J Pharmacol 107: 291–297
Steinfels GF, Tarn SW (1989) Selective σ receptor agonist and antagonist affect dopamine neuronal activity. Eur J Pharmacol 163: 167–170
Tam SW (1983) Naloxone-inaccessible a receptor in rat central nervous system. Proc Natl Acad Sci USA 80: 6703–6707
Taylor DP, Deklava J (1987) Potential antipsychotic BMY 14802 selectively binds to sigma sites. Drug Dev Res 11: 65–70
Taylor DP, Eison MS, Lobeck WG, Riblet LA, Temple DL, Yevich JP (1985) BMY 14802: a potential antipsychotic agent that dose not bind to D-2 dopamine sites. Soc Neurosci Abstr 11: 114
Ujike H, Okumura K, Zushi Y, Akiyama K, Otsuki S (1992) Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment. Eur J Pharmacol 211: 323–328
Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42: 355–402
Weber EM, Sonders M, Quarum M, McLean S, Pou S, Keana JFW (1986) 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 83: 8784–8788
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kanzaki, A., Okumura, K., Ujike, H. et al. BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine. J. Neural Transmission 90, 137–144 (1992). https://doi.org/10.1007/BF01250795
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01250795